Daiichi Sankyo
(OTC: DSNKY)
|
4:50 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $35.23 | Change: +0.34 | %Change: +0.97% | Volume: 32,872 |
Open: | $ 33.93 | Volume: | 32,872 | |
---|---|---|---|---|
High: | $ 35.23 | Yield(%) | 0.80 | |
Low: | $ 33.93 | P/E Ratio (ttm): | 48.30 | |
Dividend ($): | 0.09 | Market Cap ($): | 67.05B | |
EPS ($) | 0.73 | Shares Out: | 1.92B |
% Price Change (last 4 weeks): | -0.31 |
---|---|
% Price Change (last 13 weeks): | 14.41 |
% Price Change (last 26 weeks): | 28.20 |
% Price Change (last 52 weeks): | 10.36 |
% Price Change (year to date): | 27.33 |
Return on Equity (%): | 12.61 |
---|---|
Return on Assets (%): | 6.65 |
Return on Invested Capital (%): | 7.32 |
Gross Profit Margin (%): | 73.78 |
---|---|
Net Profit Margin (%): | 12.53 |
Operating Profit Margin (%): | 11.61 |
|
|
50-day Moving Average: | $34.43 |
---|---|
200-day Moving Average: | $30.46 |
Avg. Daily Vol. (last 50 days): | 166,755 |
Avg. Daily Vol. (last 200 days): | 134,818 |
52-wk high: | $37.72 |
52-wk low: | $23.72 |
Bid: | $n/a |
Ask: | $n/a |
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
|
Daiichi Sankyo
Daiichi Sankyo Head Office Bldg, A&B 3-5-1 Nihonbashi-honcho Chuo-Ku Tokyo TY 103-8426 Phone: 81.3.6225.1111 Fax: n/a http://www.daiichisankyo.co.jp |
Earnings (1year) ($): | 0.73 |
---|---|
Annual Dividend ($): | 0.28 |
Current P/E Ratio (ttm): | 48.30 |
Book Value ($): | 5.82 |
Cash Flow ($): | 0.96 |
Price/Earnings (x): | 48.30 |
---|---|
Price/Sales (x): | 5.49 |
Price/Book (x): | 5.45 |
Price/Cash Flow (x): | 14.68 |
Quick Ratio (x): | 2.40 |
---|---|
Current Ratio (x): | 3.01 |
LT Debt/Equity (x): | 8.48 |
Total Debt/Equity (x): | 9.24 |